FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313201830> ?p ?o ?g. }

• W4313201830 endingPage "107046" @default.
• W4313201830 startingPage "107046" @default.
• W4313201830 abstract "The increased use of digital devices has implications for health and, particularly, the eyes, due to Computer Vision Syndrome (CVS). Millions of individuals of all ages are at risk of CVS, and its prevalence ranges from 25% to 93%. This trial will evaluate the effectiveness of the Super Enhanced Single Vision Lens 01 (SESL01) versus standard single vision lens in reducing symptoms of CVS assessed by the Computer Vision Syndrome Questionnaire (CVS-Q®) scores.A double-blind, two-arm parallel randomized controlled trial will be conducted at the University of Central Lancashire, Preston (UK), recruiting students and staff with CVS-Q score ≥ 6. A 1:1 randomization and a sample size of 300 participants will be sufficient to detect a 2-point difference in the CVS-Q score between the intervention and control groups with an alpha of 5%, two-sided, allowing for a dropout of 10%. The control group will use standard single vision lenses, and the intervention group SESL01. The primary outcome to week 14 will be the difference in the CVS-Q score between SESL01 and standard single vision lenses. Secondary outcomes include the percentage of participants with CVS-Q score < 6 (no symptoms) and CVS-Q score ≥ 6 (symptoms) in the SESL01 and the standard single vision group at weeks 6, 10 and 14; the percentage of participants in each group with a total CVS-Q score < 6, 6-12, 13-19, and ≥ 20 at weeks 6, 10 and 14. The primary analysis will be the intention to treat.Findings may inform decisions about adopting the SESL01 lenses to reduce CVS.clinicaltrial.gov identifier: NCT05545878. Registered: Sept. 19, 2022." @default.
• W4313201830 created "2023-01-06" @default.
• W4313201830 creator A5000409509 @default.
• W4313201830 creator A5017127371 @default.
• W4313201830 creator A5061282910 @default.
• W4313201830 date "2023-02-01" @default.
• W4313201830 modified "2023-09-23" @default.
• W4313201830 title "Evaluation of the effectiveness of the Super Enhanced Single Vision Lens 01 (SESL01) in reducing symptoms of computer vision syndrome (CVS): A study protocol for a double-blind, two-arm parallel randomized controlled trial" @default.
• W4313201830 cites W1490164115 @default.
• W4313201830 cites W1515095890 @default.
• W4313201830 cites W1965677602 @default.
• W4313201830 cites W1968851874 @default.
• W4313201830 cites W1983114616 @default.
• W4313201830 cites W2021468868 @default.
• W4313201830 cites W2136577132 @default.
• W4313201830 cites W2171364705 @default.
• W4313201830 cites W2624315688 @default.
• W4313201830 cites W2800705505 @default.
• W4313201830 cites W2803480332 @default.
• W4313201830 cites W2911982370 @default.
• W4313201830 cites W3159539816 @default.
• W4313201830 cites W3213436170 @default.
• W4313201830 cites W3216868027 @default.
• W4313201830 cites W4280612795 @default.
• W4313201830 doi "https://doi.org/10.1016/j.cct.2022.107046" @default.
• W4313201830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36509248" @default.
• W4313201830 hasPublicationYear "2023" @default.
• W4313201830 type Work @default.
• W4313201830 citedByCount "0" @default.
• W4313201830 crossrefType "journal-article" @default.
• W4313201830 hasAuthorship W4313201830A5000409509 @default.
• W4313201830 hasAuthorship W4313201830A5017127371 @default.
• W4313201830 hasAuthorship W4313201830A5061282910 @default.
• W4313201830 hasConcept C119767625 @default.
• W4313201830 hasConcept C141071460 @default.
• W4313201830 hasConcept C142724271 @default.
• W4313201830 hasConcept C168563851 @default.
• W4313201830 hasConcept C1862650 @default.
• W4313201830 hasConcept C203092338 @default.
• W4313201830 hasConcept C204243189 @default.
• W4313201830 hasConcept C204787440 @default.
• W4313201830 hasConcept C2780385302 @default.
• W4313201830 hasConcept C2909061311 @default.
• W4313201830 hasConcept C3018954396 @default.
• W4313201830 hasConcept C71924100 @default.
• W4313201830 hasConceptScore W4313201830C119767625 @default.
• W4313201830 hasConceptScore W4313201830C141071460 @default.
• W4313201830 hasConceptScore W4313201830C142724271 @default.
• W4313201830 hasConceptScore W4313201830C168563851 @default.
• W4313201830 hasConceptScore W4313201830C1862650 @default.
• W4313201830 hasConceptScore W4313201830C203092338 @default.
• W4313201830 hasConceptScore W4313201830C204243189 @default.
• W4313201830 hasConceptScore W4313201830C204787440 @default.
• W4313201830 hasConceptScore W4313201830C2780385302 @default.
• W4313201830 hasConceptScore W4313201830C2909061311 @default.
• W4313201830 hasConceptScore W4313201830C3018954396 @default.
• W4313201830 hasConceptScore W4313201830C71924100 @default.
• W4313201830 hasLocation W43132018301 @default.
• W4313201830 hasLocation W43132018302 @default.
• W4313201830 hasOpenAccess W4313201830 @default.
• W4313201830 hasPrimaryLocation W43132018301 @default.
• W4313201830 hasRelatedWork W1932112545 @default.
• W4313201830 hasRelatedWork W1965714957 @default.
• W4313201830 hasRelatedWork W2105059445 @default.
• W4313201830 hasRelatedWork W2584850773 @default.
• W4313201830 hasRelatedWork W2611796762 @default.
• W4313201830 hasRelatedWork W2972329504 @default.
• W4313201830 hasRelatedWork W3124667968 @default.
• W4313201830 hasRelatedWork W3159466213 @default.
• W4313201830 hasRelatedWork W4247911458 @default.
• W4313201830 hasRelatedWork W4317868882 @default.
• W4313201830 hasVolume "125" @default.
• W4313201830 isParatext "false" @default.
• W4313201830 isRetracted "false" @default.
• W4313201830 workType "article" @default.